Beauty Health (SKIN)
(Delayed Data from NSDQ)
$1.40 USD
+0.11 (8.53%)
Updated Aug 15, 2024 04:00 PM ET
4-Sell of 5 4
C Value F Growth F Momentum D VGM
Income Statements
Fiscal Year end for The Beauty Health Company falls in the month of December .
All items in Millions except EPS data.
12/31/23 | 12/31/22 | 12/31/21 | 12/31/20 | 12/31/19 | |
---|---|---|---|---|---|
Sales | 398 | 366 | 260 | 0 | 167 |
Cost Of Goods | 243 | 116 | 78 | 0 | 60 |
Gross Profit | 155 | 250 | 182 | 0 | 107 |
Selling & Adminstrative & Depr. & Amort Expenses | 286 | 275 | 218 | 1 | 93 |
Income After Depreciation & Amortization | -131 | -24 | -37 | -1 | 13 |
Non-Operating Income | 43 | 83 | -329 | 0 | 1 |
Interest Expense | 14 | 13 | 12 | 0 | 17 |
Pretax Income | -102 | 45 | -377 | -1 | -3 |
Income Taxes | -2 | 1 | -2 | 0 | -1 |
Minority Interest | 0 | 0 | 0 | 0 | 0 |
Investment Gains/Losses | 0 | 0 | 0 | 0 | 0 |
Other Income/Charges | 0 | 0 | 0 | 0 | 0 |
Income From Cont. Operations | -100 | 44 | -375 | -1 | -2 |
Extras & Discontinued Operations | 0 | 0 | 0 | 0 | 0 |
Net Income (GAAP) | -100 | 44 | -375 | -1 | -2 |
Depreciation Footnote | 12/31/23 | 12/31/22 | 12/31/21 | 12/31/20 | 12/31/19 |
---|---|---|---|---|---|
Income Before Depreciation & Amortization | -92 | 3 | -11 | -1 | 29 |
Depreciation & Amortization (Cash Flow) | 39 | 27 | 25 | 0 | 15 |
Income After Depreciation & Amortization | -131 | -24 | -37 | -1 | 13 |
Earnings Per Share Data | 12/31/23 | 12/31/22 | 12/31/21 | 12/31/20 | 12/31/19 |
---|---|---|---|---|---|
Average Shares | 131.68 | 148.51 | 102.12 | NA | NA |
Diluted EPS Before Non-Recurring Items | -0.76 | -0.23 | 0.05 | NA | NA |
Diluted Net EPS (GAAP) | -0.76 | -0.23 | -3.67 | -0.09 | NA |
Fiscal Year end for The Beauty Health Company falls in the month of December .
All items in Millions except EPS data.
6/30/24 | 3/31/24 | 12/31/23 | 9/30/23 | 6/30/23 | |
---|---|---|---|---|---|
Sales | 90.59 | 81.40 | 96.82 | 97.41 | 117.48 |
Cost Of Goods | 49.65 | 33.04 | 51.14 | 109.97 | 49.60 |
Gross Profit | 40.94 | 48.36 | 45.69 | -12.55 | 67.88 |
SG&A, R&D, and Dept/Amort Expenses | 63.05 | 65.36 | 64.05 | 69.55 | 81.02 |
Income After SG&A, R&D, and Dept/Amort Expenses | -22.11 | -17.00 | -18.36 | -82.10 | -13.14 |
Non-Operating Income | 24.41 | 18.68 | 14.94 | 15.21 | 17.75 |
Interest Expense | 2.45 | 3.03 | 3.36 | 3.45 | 3.43 |
Pretax Income | -0.15 | -1.34 | -6.77 | -70.34 | 1.17 |
Income Taxes | -0.35 | -0.66 | 0.60 | 3.48 | -2.19 |
Minority Interest | NA | 0.00 | 0.00 | 0.00 | 0.00 |
Investment Gains/Losses | NA | 0.00 | 0.00 | 0.00 | 0.00 |
Other Income/Charges | NA | 0.00 | 0.00 | 0.00 | 0.00 |
Income From Cont. Operations | 0.20 | -0.68 | -7.38 | -73.82 | 3.36 |
Extras & Discontinued Operations | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Net Income (GAAP) | 0.20 | -0.68 | -7.38 | -73.82 | 3.36 |
Earnings Per Share Data | 6/30/24 | 3/31/24 | 12/31/23 | 9/30/23 | 6/30/23 |
---|---|---|---|---|---|
Average Shares | 141.93 | 144.48 | 128.72 | 132.90 | 132.72 |
Diluted EPS Before Non-Recurring Items | -0.10 | -0.10 | -0.07 | 0.05 | 0.03 |
Diluted Net EPS (GAAP) | -0.10 | -0.10 | -0.06 | -0.56 | 0.03 |